European Journal of Clinical Pharmacology

, Volume 35, Issue 2, pp 161–165 | Cite as

Effects of enoxacin, ofloxacin and norfloxacin on theophylline disposition in humans

  • M. Sano
  • K. Kawakatsu
  • C. Ohkita
  • I. Yamamoto
  • M. Takeyama
  • H. Yamashina
  • M. Goto


The effect of three new fluoroquinolones on theophylline kinetics and the urinary excretion of metabolites was studied in 5 healthy subjects (3 male, 2 female).

All subjects received serial, single i.v. infusions of theophylline (aminophylline, 250 mg) over 60 min after 200 mg doses of a quinolone (enoxacin, ofloxacin, norfloxacin) every 8 h for 3 consecutive days, the quinolone being administered up to the day following theophylline administration.

Pretreatment with ofloxacin and norfloxacin did not influence theophylline disposition, but theophylline clearance fell from 0.054 to 0.027 l·h−1·kg−1 in the presence of enoxacin, without a change in the apparent volume of distribution. Enoxacin, too, was the sole compound to increase the urinary excretion of theophylline (33.2 vs 43.9 mg, before vs after treatment), and significantly to decrease the excretion of 3-methylxanthine (3-MX), 1-methyluric acid (1-MU) and 1,3-dimethyluric acid (1,3-DMU) in 24-h urine samples (from 19.8 to 7.16 mg, from 28.3 to 10.3 mg and from 68.8 to 49.5 mg, respectively). The effect of the quinolones on hepatic drug metabolizing enzyme activity was investigated in each subject using the ratios of 6-hydroxycortisol to total 17-hydroxycorticosteroids and to free cortisol in 24-h urines as an index of the hepatic P-450-dependent enzyme system. No significant difference in ratio was observed between control and other treatments. It is concluded that the theophylline-enoxacin interaction was largely due to inhibition of a metabolic system other than the common hepatic P-450 system.

Key words

theophylline enoxacin ofloxacin norfloxacin drug metabolism/interaction hepatic P-450 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Maesen FPV, Teengs JP, Baur C, Davies BI (1984) Quinolones and raised plasma concentration of theophylline. Lancet 2: 530Google Scholar
  2. 2.
    Wijnands WJA, Vree TB, Van Herwaarden CLA (1985) Enoxacin decreases the clearance of theophylline in man. Br J Clin Pharmacol 20: 583–588Google Scholar
  3. 3.
    Fourtillan JB, Granier J, Saint-Salvi B, Salmon J, Surjus A, Tremblay D, Vincent DU, Laurier M, Beck S (1986) Pharmacokinetics of ofloxacin and theophylline alone and in combination. Infection 14 [Suppl 1]: 67–69Google Scholar
  4. 4.
    Sano M, Yamamoto I, Ueda J, Yoshikawa E, Yamashina H, Goto M (1987) Comparative pharmacokinetics of theophylline following two fluoroquinolones co-administration. Eur J Clin Pharmacol 32: 431–432Google Scholar
  5. 5.
    Tang-Liu D D-S, Riegelman S (1982) An automated HPLC assay for simultaneous quantitation of methylated xanthines and uric acids in urine. J Chromatogr Sci 20: 155–159Google Scholar
  6. 6.
    Yamada S, Iwai K (1976) Induction of hepatic cortisol-6-hydroxylase by rifampicin. Lancet 2: 366–367Google Scholar
  7. 7.
    Silver RH, Porter CC (1954) The determination of 17,21-dihydroxy-20-ketosteroids in urine and plasma. J Biol Chem 210: 923–932Google Scholar
  8. 8.
    Reddy WJ, Jenkins D, Thorn GW (1952) Estimation of 17-hydroxycorticoids in urine. Metabolism 1: 511–527Google Scholar
  9. 9.
    Yamaoka K, Tanigawara Y, Nakagawa T, Uno T (1981) A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobiodyn 4: 879–885Google Scholar
  10. 10.
    Gibaldi M, Perrier D (1975) One-compartment model. In: Pharmacokinetics. Marcel Dekker, New York, pp 1–43Google Scholar
  11. 11.
    Bolton S (1984) Analysis of variance. In: Pharmaceutical statistics. Marcel Dekker, New York, pp 218–256Google Scholar
  12. 12.
    Grygiel JJ, Miners JO, Drew R, Birkett DJ (1984) Differential effects of cimetidine on theophylline metabolic pathways. Eur J Clin Pharmacol 26: 335–340Google Scholar
  13. 13.
    Grygiel JJ, Birkett DJ, Phil D (1980) Effect of age on patterns of theophylline metabolism. Clin Pharmacol Ther 28: 456–462Google Scholar
  14. 14.
    Ogilvie RI (1978) Clinical pharmacokinetics of theophylline. Clin Pharmacokinet 3: 267–293Google Scholar
  15. 15.
    Bukowsky JM, Nakatsu K, Munt PW (1984) Theophylline reassessed. Ann Intern Med 101: 63–73Google Scholar
  16. 16.
    Ohnhaus EE, Park BK (1979) Measurement of urinary 6-β-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin. Eur J Clin Pharmacol 15: 139–145Google Scholar
  17. 17.
    Park BK, Breckenridge AM (1981) Clinical implication of enzyme induction and enzyme inhibition. Clin Pharmacokinet 6: 1–24Google Scholar
  18. 18.
    Morita K, Konishi H, Ono T, Shimakawa H (1987) A comparison of the inhibitory effects of roxatidine acetate hydrochloride and cimetidine on cytochrome P-450-mediated drug metabolism in mouse hepatic microsomes and in man in vivo. J Pharmacobiodyn 10: 287–295Google Scholar
  19. 19.
    Hunt SN, Jusko WJ, Yurchak AM (1976) Effect of smoking on theophylline disposition. Clin Pharmacol Ther 19: 546–551Google Scholar
  20. 20.
    Jenne JW, Nagasawa H, McHugh R, McDonald F, Wyse E (1975) Decreased theophylline half-life in cigarette smokers. Life Sci 17: 195–198Google Scholar
  21. 21.
    Landay RA, Gonzalez MA, Taylor JC (1978) Effect of phenobarbital on theophylline disposition. J Allergy Clin Immunol 62: 27–29Google Scholar
  22. 22.
    Challiner M, Park BK, Odum J, Orton TC (1981) The effect of 3-methylcolanthrene on urinary 6-β-hydroxycortisol excretion and hepatic enzyme activity in the marmoset monkey. Biochem Pharmacol 30: 2131–2134Google Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • M. Sano
    • 1
  • K. Kawakatsu
    • 2
  • C. Ohkita
    • 1
  • I. Yamamoto
    • 1
  • M. Takeyama
    • 2
  • H. Yamashina
    • 1
  • M. Goto
    • 3
  1. 1.Department of Hospital PharmacyTenri HospitalNaraJapan
  2. 2.Department of Hospital Pharmacy, Chest Disease Research InstituteKyoto UniversityKyotoJapan
  3. 3.Department of Hospital PharmacyNagoya Memorial HospitalNagoyaJapan

Personalised recommendations